Alex Biese

Non-melanoma skin cancer is a common and highly treatable type of cancer that originates in the top layer of the skin, like basal cell carcinoma.

Among patients with pancreatic cancer, the vaccine ELI-002 7P elicited strong mKRAS-specific T cell responses in approximately 99% of patients.

For patients with advanced GIST, complete surgical removal of metastases and full response to Gleevec are associated with roughly double the survival time.

For patients with myelofibrosis, there is a risk of non-melanoma skin cancer or shingles among patients who received long-term treatment with Jakafi.

For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as one expert explained.

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.

This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.

The FDA has accepted a new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.

The FDA has granted fast track designation to the cancer vaccine GLSI-100 for patients with HLA-A*02-positive and HER2-positive breast cancer.

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

The FDA has granted orphan drug designation to the investigational therapy BA-101 for the treatment of patients with glioblastoma.

Here is an overview of cancers including bladder cancer, kidney cancer and testicular cancer.

The FDA granted Breakthrough Therapy designation to olomorasib plus Keytruda for unresectable advanced or metastatic NSCLC with a KRAS G12C mutation.

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder cancer.

In observation of Leukemia Awareness Month in September, CURE spoke with an expert about basics of the disease.

CURE spoke with Dr. Ryan Kahn of Miami Cancer Institute for Ovarian Cancer Awareness Month.

The FDA has approved the NDA for Camcevi ETM for the treatment of advanced prostate cancer.

In HPV15-positive first-line recurrent and/or metastatic head and neck cancer, PDS0101 and Keytruda elicited median overall survival more than three years.

Here is a primer on what patients who have received a diagnosis of gastrointestinal cancer need to know.

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal cancer after surgery.

In patients with high-risk myelodysplastic syndromes, hypomethylating agents are underutilized, particularly among older, female and non-White patients.

The FDA’s accelerated approval of Modeyso for diffuse midline glioma with an H3 K27M mutation sets the stage for more treatment advancements.

This guide provides an overview of bladder cancer, from diagnosis to treatment, helping patients understand options, manage side effects, and plan care.

CURE spoke with an expert about the needs of children in families living with cancer during back-to-school season.

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung cancer.

CURE spoke with a clinical social worker about issues faced by families dealing with cancer as kids return to school.

A nationwide survey of patients and caregivers has found educational and financial disparities in brain cancer care.